search
Back to results

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

Primary Purpose

Stroke, Acute, Neurological Impairment

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
EGb761
Placebo
Acetylsalicylic acid
Sponsored by
Ipsen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient having had a single infarct in the carotid artery territory 3 to 8 days before inclusion Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5) Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time) test in the normal values of the laboratory Exclusion Criteria: Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8 days prior Patient with known pre-existent cerebral infarction Infarct damaged area bigger than 1/3 hemisphere Patient having a score below the cut-off point at Frenchay Aphasia Short Test

Sites / Locations

  • Faculty of Medicine in Hradec Kralove
  • General Faculty Hospital
  • Department and Clinic of Neurology of the Old Age
  • CMUJ Krakov
  • Postgraduate Medical Teaching Center
  • Institul de Boli Cerebro Vascular
  • Spitalul Universitar de Urgenta
  • Russian State Medical University - Neurology and Neurosurgery Clinic
  • Russian State Medical University - Dept Fundamental Neurology & Neurosurgery
  • Ural State Medical Academy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

EGb761®

Placebo

Arm Description

EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day). The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.

6 months, administered orally, in association with acetylsalicylic acid (325 mg/day). The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.

Outcomes

Primary Outcome Measures

Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period.
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale. The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The percentage of subjects having a modified Rankin Score<3 at the end of the study (Day 168) are reported.

Secondary Outcome Measures

Percentage of Subjects With Modified Rankin Score of Less Than 3 at Day 28 and Day 84.
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale. The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The percentage of subjects having a modified Rankin Score<3 at each follow-up visit (not including end of study) are reported.
Percentage of Subjects at Each Point on the Modified Rankin Scale at Baseline, Day 28, Day 84 and Day 168.
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale.The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability,3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The distribution of subjects according to disability severity scores was assessed and the percentage of subjects at each point on the modified Rankin scale are reported for each time point.
Mean Change From Baseline in Sandoz Clinical Assessment-Geriatric (SCAG) Scores at Day 28, Day 84 and Day 168.
The SCAG scale was to be used to evaluate the psychopathological state of the subject. It is composed of 18 symptom areas and an overall global assessment, all rated on a 7-point format from 1=not present to 7=severe. The total score range is from 19 to 133 (best to worst), with a negative mean change from baseline indicating an improvement in symptoms. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Mean Change From Baseline in Barthel Index Scores at Day 28, Day 84 and Day 168.
The performance in activities of daily living was assessed by using the Barthel scale. The Barthel scale is an ordinal scale which measures 10 performance items describing activities of daily living. Each item is rated with a given number of points from 0 indicating total dependence up to a maximum of 10 or 15 (depending on performance item) indicating complete independence. The total score range is from 0 to 100 (worst to best), with a positive mean change indicating an improvement in independence. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Mean Change From Baseline in the Mini Mental State (MMS) Test Scores at Day 28, Day 84 and Day 168.
The MMS test was used to evaluate the cognitive function of the subject. It includes tests of orientation, attention, memory, language and visual spatial skills, which are rated with a given number of points assigned to each level or ranking. The lower the score, the more important the mental deficit. The total score range is from 0 to 30 (worst to best), with a positive mean change indicating an improvement (i.e. less mental deficit). Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Mean Change From Baseline in the National Institute of Health Stroke Scale (NIHSS) Subscore for Questions 1a,1b and 1c at Day 28, Day 84 and Day 168.
The NIHSS was to be used to objectively quantify the impairment caused by the stroke.The NIHSS is composed of 11 items, each of which score a specific ability between 0 (normal function) and 4 (high level of impairment).The minimum total score is 0 and maximum is 42. Only 8 of the NIHSS subscores were calculated for this study. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. Mean NIHSS subscores for questions 1a (level of consciousness),1b (asking patient the month and their age), and 1c (asking to open and close eyes) were analysed using descriptive quantitative statistics at each visit and the mean change from baseline at each time point is reported. The range for the subscore for items 1a is 0 - 3, for 1b is 0 - 2 and for 1c is 0 - 2 (best to worst), with a negative mean change from baseline indicating an improvement.

Full Information

First Posted
January 12, 2006
Last Updated
January 4, 2019
Sponsor
Ipsen
search

1. Study Identification

Unique Protocol Identification Number
NCT00276380
Brief Title
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
Official Title
A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ipsen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute, Neurological Impairment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
204 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EGb761®
Arm Type
Experimental
Arm Description
EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day). The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
6 months, administered orally, in association with acetylsalicylic acid (325 mg/day). The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.
Intervention Type
Drug
Intervention Name(s)
EGb761
Other Intervention Name(s)
Tanakan
Intervention Description
EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Intervention Type
Drug
Intervention Name(s)
Acetylsalicylic acid
Intervention Description
Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Primary Outcome Measure Information:
Title
Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period.
Description
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale. The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The percentage of subjects having a modified Rankin Score<3 at the end of the study (Day 168) are reported.
Time Frame
Day 168
Secondary Outcome Measure Information:
Title
Percentage of Subjects With Modified Rankin Score of Less Than 3 at Day 28 and Day 84.
Description
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale. The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The percentage of subjects having a modified Rankin Score<3 at each follow-up visit (not including end of study) are reported.
Time Frame
Up to Day 84
Title
Percentage of Subjects at Each Point on the Modified Rankin Scale at Baseline, Day 28, Day 84 and Day 168.
Description
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale.The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability,3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The distribution of subjects according to disability severity scores was assessed and the percentage of subjects at each point on the modified Rankin scale are reported for each time point.
Time Frame
Up to Day 168
Title
Mean Change From Baseline in Sandoz Clinical Assessment-Geriatric (SCAG) Scores at Day 28, Day 84 and Day 168.
Description
The SCAG scale was to be used to evaluate the psychopathological state of the subject. It is composed of 18 symptom areas and an overall global assessment, all rated on a 7-point format from 1=not present to 7=severe. The total score range is from 19 to 133 (best to worst), with a negative mean change from baseline indicating an improvement in symptoms. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Time Frame
Up to Day 168
Title
Mean Change From Baseline in Barthel Index Scores at Day 28, Day 84 and Day 168.
Description
The performance in activities of daily living was assessed by using the Barthel scale. The Barthel scale is an ordinal scale which measures 10 performance items describing activities of daily living. Each item is rated with a given number of points from 0 indicating total dependence up to a maximum of 10 or 15 (depending on performance item) indicating complete independence. The total score range is from 0 to 100 (worst to best), with a positive mean change indicating an improvement in independence. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Time Frame
Up to Day 168
Title
Mean Change From Baseline in the Mini Mental State (MMS) Test Scores at Day 28, Day 84 and Day 168.
Description
The MMS test was used to evaluate the cognitive function of the subject. It includes tests of orientation, attention, memory, language and visual spatial skills, which are rated with a given number of points assigned to each level or ranking. The lower the score, the more important the mental deficit. The total score range is from 0 to 30 (worst to best), with a positive mean change indicating an improvement (i.e. less mental deficit). Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168 and the mean change from baseline at each time point is reported.
Time Frame
Up to Day 168
Title
Mean Change From Baseline in the National Institute of Health Stroke Scale (NIHSS) Subscore for Questions 1a,1b and 1c at Day 28, Day 84 and Day 168.
Description
The NIHSS was to be used to objectively quantify the impairment caused by the stroke.The NIHSS is composed of 11 items, each of which score a specific ability between 0 (normal function) and 4 (high level of impairment).The minimum total score is 0 and maximum is 42. Only 8 of the NIHSS subscores were calculated for this study. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. Mean NIHSS subscores for questions 1a (level of consciousness),1b (asking patient the month and their age), and 1c (asking to open and close eyes) were analysed using descriptive quantitative statistics at each visit and the mean change from baseline at each time point is reported. The range for the subscore for items 1a is 0 - 3, for 1b is 0 - 2 and for 1c is 0 - 2 (best to worst), with a negative mean change from baseline indicating an improvement.
Time Frame
Up to Day 168

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient having had a single infarct in the carotid artery territory 3 to 8 days before inclusion Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5) Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time) test in the normal values of the laboratory Exclusion Criteria: Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8 days prior Patient with known pre-existent cerebral infarction Infarct damaged area bigger than 1/3 hemisphere Patient having a score below the cut-off point at Frenchay Aphasia Short Test
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ipsen Medical Director
Organizational Affiliation
Ipsen
Official's Role
Study Director
Facility Information:
Facility Name
Faculty of Medicine in Hradec Kralove
City
Hradec Kralove
ZIP/Postal Code
500 02
Country
Czechia
Facility Name
General Faculty Hospital
City
Prague 2
ZIP/Postal Code
120 00
Country
Czechia
Facility Name
Department and Clinic of Neurology of the Old Age
City
Katowice
ZIP/Postal Code
40 752
Country
Poland
Facility Name
CMUJ Krakov
City
Krakov
ZIP/Postal Code
31503
Country
Poland
Facility Name
Postgraduate Medical Teaching Center
City
Warsaw
ZIP/Postal Code
00 416
Country
Poland
Facility Name
Institul de Boli Cerebro Vascular
City
Bucharest
ZIP/Postal Code
75622
Country
Romania
Facility Name
Spitalul Universitar de Urgenta
City
Bucharest
ZIP/Postal Code
Sector 5
Country
Romania
Facility Name
Russian State Medical University - Neurology and Neurosurgery Clinic
City
Moscow
ZIP/Postal Code
117415
Country
Russian Federation
Facility Name
Russian State Medical University - Dept Fundamental Neurology & Neurosurgery
City
Moscow
ZIP/Postal Code
129327
Country
Russian Federation
Facility Name
Ural State Medical Academy
City
Yekaterinburg
ZIP/Postal Code
620102
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

We'll reach out to this number within 24 hrs